Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Mar 22;51(3):1800170.
doi: 10.1183/13993003.00170-2018. Print 2018 Mar.

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement

Jakko van Ingen  1 , Timothy Aksamit  2 , Claire Andrejak  3   4 , Erik C Böttger  5 , Emmanuelle Cambau  6 , Charles L Daley  7 , David E Griffith  8 , Lorenzo Guglielmetti  9   10 , Steven M Holland  11 , Gwen A Huitt  7 , Won-Jung Koh  12 , Christoph Lange  13   14   15   16 , Philip Leitman  17 , Theodore K Marras  18 , Kozo Morimoto  19 , Kenneth N Olivier  20 , Miguel Santin  21 , Jason E Stout  22 , Rachel Thomson  23   24 , Enrico Tortoli  25 , Richard J Wallace Jr  26 , Kevin L Winthrop  27 , Dirk Wagner  28 ; for NTM-NET
Affiliations
Editorial

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement

Jakko van Ingen et al. Eur Respir J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: E. Cambau has received non-financial support for travel from ESCMID, during the conduct of the study. Conflict of interest: C.L. Daley has received grants and personal fees from Insmed, outside the submitted work. Conflict of interest: C. Lange has received personal fees for independent lectures at sponsored symposia from Chiesi, Gilead, Abbvie, MSD, Becton Dickinson, Janssen, Lucane, Novartis and Thermofisher, outside the submitted work. Conflict of interest: T.K.. Marras has received grants from Insmed (site investigator for clinical trial, funds paid to institution), personal fees for consultancy (for designing clinical trials in NTM lung disease, with all funds paid to institution) from Insmed and RedHill, and personal fees from AstraZeneca (honoraria for CME on mycobacterial disease, funds paid to institution), outside the submitted work. Conflict of interest: K. Morimoto has received personal fees for consultancy from INSMED, outside the submitted work. Conflict of interest: K.N. Olivier received grants from Insmed Inc. and Matinas Biopharma, during the conduct of the study. Conflict of interest: R. Thomson received consultancy fees for work unrelated to this manuscript from Insmed and Savara.

References

    1. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis 2016; 45: 123–134. - PubMed
    1. Griffith DE, Aksamit T, Brown-Elliot BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416. - PubMed
    1. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71: Suppl. 1, 1–22. - PMC - PubMed
    1. Olivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med 2017; 195: 814–823. - PMC - PubMed
    1. van Ingen J, Ferro BE, Hoefsloot W, et al. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther 2013; 11: 1065–1077. - PubMed

Publication types

MeSH terms